ANGO

SEC source: 0001140361-18-033947 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,760

F1 · shares: The exempt disposition of 276 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001140361-18-033940 · doc1.xml · nonDerivative · entry 1

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,123

F1 · shares: The exempt disposition of 308 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001140361-18-033944 · doc1.xml · nonDerivative · entry 1

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,670

F1 · shares: The exempt disposition of 511 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001140361-18-033950 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,145

F2 · shares: The exempt disposition of 391 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 25, 2014.

SEC source: 0001140361-18-033950 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,536

F1 · shares: The exempt disposition of 355 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 22, 2015.

SEC source: 0001140361-18-033075 · doc1.xml · nonDerivative · entry 1

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,209

F1 · shares: The acquisition of 6,307 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,307 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/18/2019.

SEC source: 0001140361-18-033089 · doc1.xml · nonDerivative · entry 1

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,599

F1 · shares: The acquisition of 6,307 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,307 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/18/2019.

SEC source: 0001140361-18-033093 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,938

Underlying: Common Stock · 34,938 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-18-033093 · doc1.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,651

Underlying: Common Stock · 55,651 shares

Expires 2028-07-18

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 18, 2019, such that 25% of the options will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033093 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,286

F1 · shares: This acquisition of 17,469 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 17,469 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 18, 2019, such that 25% of the restricted stock units will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033079 · doc1.xml · nonDerivative · entry 1

Auen Eileen O'Shea · CIK 0001428073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,283

F1 · shares: The acquisition of 6,307 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,307 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/18/2019.

SEC source: 0001140361-18-033087 · doc1.xml · nonDerivative · entry 1

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,978

F1 · shares: The acquisition of 6,307 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,307 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/18/2019.

SEC source: 0001140361-18-033083 · doc1.xml · nonDerivative · entry 1

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,962

F1 · shares: The acquisition of 6,307 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,307 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/18/2019.

SEC source: 0001140361-18-033077 · doc1.xml · nonDerivative · entry 1

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,489

F1 · shares: The acquisition of 6,307 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,307 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/18/2019.

SEC source: 0001140361-18-033099 · doc1.xml · derivative · entry 3

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,496

Underlying: Common Stock · 9,496 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-18-033099 · doc1.xml · derivative · entry 2

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,126

Underlying: Common Stock · 15,126 shares

Expires 2028-07-18

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 18, 2019, such that 25% of the options will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033099 · doc1.xml · nonDerivative · entry 1

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,431

F1 · shares: This acquisition of 4,748 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 4,748 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 18, 2019, such that 25% of the restricted stock units will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033095 · doc1.xml · derivative · entry 3

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,975

Underlying: Common Stock · 13,975 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-18-033095 · doc1.xml · derivative · entry 2

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,260

Underlying: Common Stock · 22,260 shares

Expires 2028-07-18

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 18, 2019, such that 25% of the options will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033095 · doc1.xml · nonDerivative · entry 1

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,181

F1 · shares: This acquisition of 6,988 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,988 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 18, 2019, such that 25% of the restricted stock units will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033097 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,437

Underlying: Common Stock · 9,437 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-18-033097 · doc1.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,032

Underlying: Common Stock · 15,032 shares

Expires 2028-07-18

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 18, 2019, such that 25% of the options will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033097 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,891

F1 · shares: This acquisition of 4,719 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 4,719 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 18, 2019, such that 25% of the restricted stock units will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033091 · doc1.xml · derivative · entry 3

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,079

Underlying: Common Stock · 7,079 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-18-033091 · doc1.xml · derivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,276

Underlying: Common Stock · 11,276 shares

Expires 2028-07-18

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 18, 2019, such that 25% of the options will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033091 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,036

F1 · shares: This acquisition of 3,539 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,539 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 18, 2019, such that 25% of the restricted stock units will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033081 · doc1.xml · nonDerivative · entry 1

Gould Kevin J · CIK 0001504093 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,124

F1 · shares: The acquisition of 6,307 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,307 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/18/2019.

SEC source: 0001140361-18-033085 · doc1.xml · nonDerivative · entry 1

LaPorte Steve · CIK 0001340404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,484

F1 · shares: The acquisition of 6,307 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,307 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/18/2019.

SEC source: 0001567619-18-001675 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,737 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 22, 2015, the reporting person received a target grant of 5,737 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2016, 2017 and 2018. Based on the Company's performance over this period, 3,556 shares of Common Stock were issued to the reporting person under this grant.

F3 · derivative.exercise_date: On July 22, 2015, the reporting person received a target grant of 5,737 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2016, 2017 and 2018. Based on the Company's performance over this period, 3,556 shares of Common Stock were issued to the reporting person under this grant.

F3 · derivative.expiration_date: On July 22, 2015, the reporting person received a target grant of 5,737 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2016, 2017 and 2018. Based on the Company's performance over this period, 3,556 shares of Common Stock were issued to the reporting person under this grant.

SEC source: 0001567619-18-001675 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,935

F2 · shares: The exempt disposition of 1,175 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 22, 2015.

SEC source: 0001567619-18-001675 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,110

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 3,556 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 22, 2015.

SEC source: 0001140361-18-032062 · doc1.xml · derivative · entry 3

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,000 shares

Expires 2018-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-third of the shares became exercisable on 8/3/2012, 8/3/2013 and 8/3/2014, respectively.

SEC source: 0001140361-18-032062 · doc1.xml · nonDerivative · entry 2

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,902

SEC source: 0001140361-18-032062 · doc1.xml · nonDerivative · entry 1

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,906

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-029780 · doc1.xml · derivative · entry 3

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,000 shares

Expires 2018-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-third of the shares became exercisable on 8/3/2012, 8/3/2013 and 8/3/2014, respectively.

SEC source: 0001140361-18-029780 · doc1.xml · nonDerivative · entry 2

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,655

SEC source: 0001140361-18-029780 · doc1.xml · nonDerivative · entry 1

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-029784 · doc1.xml · derivative · entry 3

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,000 shares

Expires 2018-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-third of the shares became exercisable on 8/3/2012, 8/3/2013 and 8/3/2014, respectively.

SEC source: 0001140361-18-029784 · doc1.xml · nonDerivative · entry 2

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,906

SEC source: 0001140361-18-029784 · doc1.xml · nonDerivative · entry 1

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,134

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-029791 · doc1.xml · derivative · entry 3

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,000 shares

Expires 2018-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-third of the shares are each exercisable on 8/3/2012, 8/3/2013 and 8/3/2014, respectively.

SEC source: 0001140361-18-029791 · doc1.xml · nonDerivative · entry 2

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,671

SEC source: 0001140361-18-029791 · doc1.xml · nonDerivative · entry 1

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-029787 · doc1.xml · derivative · entry 3

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,650 shares

Expires 2019-08-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 8/7/2013, 8/7/2014, 8/7/2015 and 8/7/2016, respectively.

SEC source: 0001140361-18-029787 · doc1.xml · nonDerivative · entry 2

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,182

SEC source: 0001140361-18-029787 · doc1.xml · nonDerivative · entry 1

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-025601 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,497

F1 · shares: The exempt disposition of 827 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001140361-18-019564 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,172

F1 · shares: The exempt disposition of 1,280 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on April 24, 2015.

SEC source: 0001140361-18-004709 · doc1.xml · nonDerivative · entry 1

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,683

F1 · shares: The exempt disposition of 1,056 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on January 31, 2017.

SEC source: 0001140361-17-043659 · doc1.xml · derivative · entry 3

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,000 shares

Expires 2018-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-third of the shares became exercisable on August 3, 2012, August 3, 2013 and August 3, 2014, respectively.